Bruno F.
- Country
- Italy
- Department
- SC Ematologia
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Phase 2a Study of Tafasitamab in Adults with Primary Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia
- A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Data & Insights
Has run more than one trial at 130 of 278 partner sites.
Specializations
Myelodysplastic Syndrome Research
The investigator specializes in treating myelodysplastic syndromes (MDS), with particular focus on managing anemia in lower-risk MDS patients. Their research encompasses both transfusion-dependent and non-transfusion dependent cases.
- Del5q MDS variants
- Low and intermediate-risk MDS management
- Novel therapeutic approaches for MDS-related anemia
Autoimmune Hematologic Disorders
The investigator has extensive experience in treating various forms of autoimmune cytopenias, including specialized research in warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD).
- Primary immune thrombocytopenia
- Autoimmune hemolytic anemia variants
- Novel immunomodulatory therapies
Rare Hematologic Conditions
The investigator conducts research in rare blood disorders, including paroxysmal nocturnal hemoglobinuria (PNH) and indolent systemic mastocytosis.
- Complement inhibitor therapies
- Systemic mastocytosis management
- Innovative treatment approaches for rare blood disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.